Balle V, Illum P
Acta Otolaryngol. 1977 Sep-Oct;84(3-4):287-91. doi: 10.3109/00016487709123969.
In a double-blind crossover trial, 24 patients with perennial rhinitis have been treated with 2% disodium cromoglycate (DSCG) nasal spray. 15 patients preferred DSCG to placebo, 9 patients showed no preference. Analysis of the diary cards showed a significant preference of DSCG in the group which received placebo first for the symptoms blocking, secretion and sneezing (p less than 0.1), while no preference between the treatment periods occured in the group receiving DSCG first. A significantly higher IgG concentration in serum was found in 15 patients with preference for DSCG than with remainder (p less than 0.05). No other changes in immunoglobulin concentration in nasal secretion or serum were found, which could be related to the effect of DSCG. DSCG nasal spray is considered a valuable supplement in the treatment of perennial rhinitis.
在一项双盲交叉试验中，24例常年性鼻炎患者接受了2%色甘酸钠二钠（DSCG）鼻喷雾剂治疗。15例患者更喜欢DSCG而非安慰剂，9例患者无偏好。对日记卡的分析显示，在首先接受安慰剂治疗的组中，DSCG在症状阻塞、分泌物和打喷嚏方面有显著偏好（p小于0.1），而在首先接受DSCG治疗的组中，治疗期间无偏好。在15例偏好DSCG的患者中，发现血清中IgG浓度显著高于其余患者（p小于0.05）。未发现鼻分泌物或血清中免疫球蛋白浓度有其他与DSCG作用相关的变化。DSCG鼻喷雾剂被认为是常年性鼻炎治疗中的一种有价值的补充药物。
